Background and Purpose: Factor (F) XIII is a transglutaminase which stabilizes fibrin clots by forming cross-links between chains of fibrin. A common Val34Leu polymorphism of FXIII is correlated with the level of activated plasma FXIII. The homozygous 34Val genotype may be associated with an increased risk for thrombosis by forming fibrin fibers more resistant to fibrinolysis. The aim of the study was to investigate the association between the FXIII Val34Leu polymorphism and the risk of ischemic stroke due to small vessel disease (SVD) or the risk of primary intracerebral hemorrhage (PICH). Methods: 66 patients with SVD stroke and 135 age- and sex-matched controls as well as 64 patients with PICH and their 127 controls were included. The FXIII Val34Leu polymorphism was genotyped using the polymerase chain reaction and restriction enzyme digestion methods. Results: The homozygous 34Val genotype was found significantly more often in patients with SVD stroke than in their controls (62 vs. 42%). On multivariate analysis, the Val/Val genotype was associated with an increased risk of SVD stroke (odds ratio: 2.1, 95% confidence interval: 1.1–3.9). The genotype distribution did not differ significantly between PICH patients and their controls (50 vs. 43%). Conclusion: Our results suggest that the Val/Val genotype of FXIII could be associated with an increased risk of SVD stroke.

Keywords:
Stroke, Genetics, Factor XIII polymorphism
1.
Ichinose A: Physiology and regulation of factor XIII. Thromb Haemost 2001;86:57–65.
2.
Kangsadalampai S, Board PG: The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998;92:2766–2770.
3.
Kohler HP, Ariens RA, Whitaker P, Grant PJ: A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity (letter). Thromb Haemost 1998;80:704.
4.
Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ: The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000;96:988–995.
5.
Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ: Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Heamost 1998;79:8–13.
6.
Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A: Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999;142:295–300.
7.
Franco RF, Reitsma PH, Lourenco D, Maffei FH, Morelli V, Tavella MH, Araujo AG, Piccinato CE, Zago MA: Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost 1999;81:676–679.
8.
Weger M, Renner W, Stanger O, Schmut O, Deutschmann H, Wascher TC, Haas A: Role of factor XIII Val34Leu polymorphism in retinal artery occlusion. Stroke 2001;32:2759–2761.
9.
Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P: The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000;95:586–591.
10.
Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ: Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage. Stroke 1998;29:813–816.
11.
Lim BCB, Ariens RAS, Carter AM, Weisel JW, Grant PJ: Genetic regulation of fibrin structure and function: Complex gene-environment interactions may modulate vascular risk. Lancet 2003;361:1424–1431.
12.
Hantano S: Experience from multicentre stroke register: A preliminary report. Bull World Health Organ 1976;54:541–553.
13.
Adams HP, Bendixen BH, Kappelle LJ, and the TOAST Investigators: Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. Stroke 1993;24:35–41.
14.
Alberti KG, Zimmet PZ: Definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus – Provisional report of a WHO consultation. Diabet Med 1998;15:539–553.
15.
Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R, Moretti M, Scapoli GL: A common mutation in the gene for coagulation factor XIII-A (Val34Leu): A risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 2001;67:183–188.
16.
Corral J, Gonzalez-Conejero R, Iniesta JA, Rivera J, Martinez C, Vicente V: The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Hematologica 2000;85:293–297.
17.
Endler G, Funk M, Haering D, Lalouschek W, Lang W, Mirafzal M, Wagner O, Mannhalter C: Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease? Br J Haematol 2003;120:310–314.
18.
Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth WT Jr, Teramura G, Rosendaal FR, Psaty BM, Siscovick DS: Coagulation factor XIII polymorphism and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 2002;116:376–382.
19.
Jerrard-Dunne P, Cloud G, Hassan A, Markus HS: Evaluating the genetic component of ischemic stroke subtypes: A family history study. Stroke 2003;34:1364–1369.
20.
Attie-Castro FA, Zago MA, Lavinha J, Elion J, Rodriguez-Delfin L, Guerreiro JF, Franco RF: Ethnic heterogeneity of the factor XIII Val34Leu polymorphism. Thromb Haemost 2000;84:601–603.
21.
Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T: Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health 2003;57:730–733.
22.
Corral J, Iniesta JA, Gonzalez-Conejero R, Villalon M, Vicente V: Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 2001;97:2979–2982.
23.
Cho KH, Kim BC, Kim MK, Shin BA: No association of factor XIII Val34Leu polymorphism with primary intracerebral hemorrhage and healthy controls in Korean population. J Korean Med Sci 2002;17:249–253.
24.
Howard G, Wagenknecht LE, Cai J, Cooper L, Kraut MA, Toole JF: Cigarette smoking and other risk factors for silent cerebral infarction in the general population. Stroke 1998;29:913–917.
25.
Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB: Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21–25.
26.
Eguchi K, Kario K, Shimada K: Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke 2003;34:2471–2474.
27.
Uehara T, Tabuchi M, Mori E: Risk factors for silent cerebral infarcts in subcortical white matter and basal ganglia. Stroke 1999;30:378–382.
28.
Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, Beauchamp N, Price T, Cardiovascular Health Study Collaborative Reseach Group: Silent MRI infarcts and the risk of future stroke: The cardiovascular health study. Neurology 2001;57:1222–1229.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.